Eric Bartee

University of New Mexico — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.4kcitations81works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(52), CAR-T cell therapy research(32), Immunotherapy and Immune Responses(16), Cancer Research and Treatments(16), Viral Infectious Diseases and Gene Expression in Insects(10)

Publications81 total

The potential for p53 reactivators to increase the sensitivity of aggressive gynecologic cancers to immunotherapy 3272
The Journal of Immunology·2025Open Access
B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity
UNC Libraries·2025Open Access
Myeloid-derived suppressor cells inhibit the replication of oncolytic virus by reducing intratumoral arginine levels
Molecular Therapy Oncology·2025Open Access
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Journal for ImmunoTherapy of Cancer·2025Open Access
Killing cancer quickly: inducing hyper-acute rejection of patient tumors
Cell Research·2025Open Access
TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer (Adv. Healthcare Mater. 7/2025)
Advanced Healthcare Materials·2025Open Access
Navigating a complex dance: the interplay between RNA-binding proteins and T cells in oral epithelial plasticity
Immunometabolism·2025Open Access
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration
OncoImmunology·2024· 1 citedOpen Access
TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer
Advanced Healthcare Materials·2024· 8 citedOpen Access
IL-12-mediated toxicity from localized oncolytic virotherapy can be reduced using systemic TNF blockade
Molecular Therapy Oncology·2024· 2 citedOpen Access
1218 Selective internalization of microbial mimetic mesoporous silica nanoparticles by myeloid-derived suppressor cells with trafficking to tumor-burdened tissues in a mouse model of ovarian cancer
Regular and Young Investigator Award Abstracts·2023Open Access
Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection
Molecular Therapy — Oncolytics·2023· 4 citedOpen Access
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
Journal for ImmunoTherapy of Cancer·2023· 7 citedOpen Access
Supplemental Figure legends from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
Supplemental Figure 6 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
Supplemental Figure 5 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
Supplemental Figure 2 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
Data from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
Data from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
Supplemental Figure 7 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Grant McFadden(14), Mee Y. Bartee(14), Klaus Früh(8), Erica Flores(7), Masmudur M. Rahman(6), Mohamed R. Mohamed(5), Katherine M. Dunlap(5), Mandana Mansouri(4), Kristine Gouveia(4), Christopher R. Cogle(4), Parker Dryja(4), Bianca T. Hovey Nerenberg(3), John W. Barrett(3), Miriam Valenzuela-Cardenas(3), Henning De May(3), Lorél Y. Medina(3), Rita E. Serda(3), Connor J. Dwyer(2), Hannah M. Knochelmann(2), Aubrey S. Smith(2)